Loading
A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer is a phase 2 interventional study registered as NCT05999994 by Eli Lilly and Company, with 105 participants planned, started 2020-01-22 and due to reach its primary completion in 2027-05. Interventions recorded: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Docetaxel, Gemcitabine and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Metastatic cancer (cancer that has spread) and the tag pipeline.